Tags

Type your tag names separated by a space and hit enter

Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis.
Eur J Cancer. 2001 Nov; 37(16):2003-9.EJ

Abstract

The combination of radiation and chemotherapy administered for patients undergoing therapy for advanced head and neck neoplasms leads to a significant rise in toxic side-effects. Oral mucositis remains one of the most distressing factors leading to pain, impairment of oral nutrition, local and systemic infection and often cessation of the oncological treatment. The local and systemic administration of recombinant growth factors has revealed a potential benefit in the treatment of oral mucositis. Clinical data concerning the topical use of granulocyte-macrophage colony-stimulating-factor (GM-CSF) in the prevention and therapy of mucositis in patients undergoing radiochemotherapy for advanced cancer of the head and neck are presented in this paper. A prospective, randomised, open parallel-grouped, single centre study at a university hospital was performed. 35 patients with stage III and IV carcinomas of the head and neck were included. Statistical analysis concerning the degree of oral mucositis, the perception of pain, the incidence of secondary infections and the change in haematological parameters revealed no superiority of GM-CSF in comparison to conventional mouthwash between the two groups of patients. As a result, and faced with the tremendous costs of the regular use of a recombinant cytokine, we ended the clinical trial after 35 patients. The topical administration of GM-CSF to treat oral mucositis as a result of radiochemotherapy in patients suffering from head and neck cancer cannot be recommended.

Authors+Show Affiliations

Department of Oto-Rhino-Laryngology-Head and Neck Surgery, University of Innsbruck, Austria. georg.sprinzl@uibk.ac.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11597377

Citation

Sprinzl, G M., et al. "Local Application of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for the Treatment of Oral Mucositis." European Journal of Cancer (Oxford, England : 1990), vol. 37, no. 16, 2001, pp. 2003-9.
Sprinzl GM, Galvan O, de Vries A, et al. Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. Eur J Cancer. 2001;37(16):2003-9.
Sprinzl, G. M., Galvan, O., de Vries, A., Ulmer, H., Gunkel, A. R., Lukas, P., & Thumfart, W. F. (2001). Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. European Journal of Cancer (Oxford, England : 1990), 37(16), 2003-9.
Sprinzl GM, et al. Local Application of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for the Treatment of Oral Mucositis. Eur J Cancer. 2001;37(16):2003-9. PubMed PMID: 11597377.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Local application of granulocyte-macrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis. AU - Sprinzl,G M, AU - Galvan,O, AU - de Vries,A, AU - Ulmer,H, AU - Gunkel,A R, AU - Lukas,P, AU - Thumfart,W F, PY - 2001/10/13/pubmed PY - 2002/1/5/medline PY - 2001/10/13/entrez SP - 2003 EP - 9 JF - European journal of cancer (Oxford, England : 1990) JO - Eur. J. Cancer VL - 37 IS - 16 N2 - The combination of radiation and chemotherapy administered for patients undergoing therapy for advanced head and neck neoplasms leads to a significant rise in toxic side-effects. Oral mucositis remains one of the most distressing factors leading to pain, impairment of oral nutrition, local and systemic infection and often cessation of the oncological treatment. The local and systemic administration of recombinant growth factors has revealed a potential benefit in the treatment of oral mucositis. Clinical data concerning the topical use of granulocyte-macrophage colony-stimulating-factor (GM-CSF) in the prevention and therapy of mucositis in patients undergoing radiochemotherapy for advanced cancer of the head and neck are presented in this paper. A prospective, randomised, open parallel-grouped, single centre study at a university hospital was performed. 35 patients with stage III and IV carcinomas of the head and neck were included. Statistical analysis concerning the degree of oral mucositis, the perception of pain, the incidence of secondary infections and the change in haematological parameters revealed no superiority of GM-CSF in comparison to conventional mouthwash between the two groups of patients. As a result, and faced with the tremendous costs of the regular use of a recombinant cytokine, we ended the clinical trial after 35 patients. The topical administration of GM-CSF to treat oral mucositis as a result of radiochemotherapy in patients suffering from head and neck cancer cannot be recommended. SN - 0959-8049 UR - https://www.unboundmedicine.com/medline/citation/11597377/Local_application_of_granulocyte_macrophage_colony_stimulating_factor__GM_CSF__for_the_treatment_of_oral_mucositis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0959804901001708 DB - PRIME DP - Unbound Medicine ER -